Tainan City, Taiwan, July 17, 2018 — Handa Pharmaceuticals, Inc. (Taiwan Exchange: 6620) (“Handa”), summons an investor meeting to present the following information to institutional investors. “Handa is pleased to announce the rollout of its unique and creative ONCORE® drug delivery technology platform” applicable to the development of 505 (b)(2) new drugs, said Bill Liu,...Read More